T cell ex­perts at Kiadis bag Cy­toSen's NK cell tech, plot­ting a dual can­cer killing ap­proach with tips from Carl June

In an ef­fort to mar­ry T cell and nat­ur­al killer cell tech­nolo­gies for the treat­ment of blood can­cer, Dutch biotech Kiadis has inked an all-stock deal to ac­quire US-based Cy­toSen Ther­a­peu­tics.

Both com­pa­nies have had the same goal: to boost the chances of can­cer pa­tients un­der­go­ing hematopoi­et­ic stem cell trans­plants by su­per­charg­ing their im­mune sys­tem while their bone mar­row re­cov­ers from the pro­ce­dure. Kiadis does this with en­gi­neered T cells; Cy­toSen chose NK cells, de­signed to at­tack any re­main­ing ma­lig­nant cells that could lead to a re­lapse. Both tech­nolo­gies take cells from a fam­i­ly mem­ber of the pa­tient so that the im­mune cells would be par­tial­ly matched.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.